نتایج جستجو برای: sofosbuvir
تعداد نتایج: 1451 فیلتر نتایج به سال:
BACKGROUND & AIMS We performed a phase 2 trial of the efficacy and safety of 4, 6, and 8 weeks of sofosbuvir, given in combination with the NS5A inhibitor velpatasvir and the NS3/4A protease inhibitor GS-9857, in patients with hepatitis C virus (HCV) infection. METHODS We enrolled 161 treatment-naïve or previously treated patients infected with HCV genotypes 1 or 3 with or without compensated...
Hepatitis C virus (HCV) is a positivestrand RNA virus that infects >170 million people worldwide, including approximately 3.2 million people in the United States. Chronic HCV infection can result in chronic inflammation, liver damage, and death, with 350 000 deaths per year globally. The most exciting advance in antiviral therapy in the last decade has been the development of direct-acting anti...
Treatment of hepatitis C virus with potent, interferon-free, direct-acting antiviral regimens with no activity against hepatitis B virus (HBV) may increase the risk for HBV reactivation in coinfected patients. We present 2 cases of HBV reactivation during treatment with an all-oral regimen of simeprevir and sofosbuvir and discuss strategies to prevent HBV flare.
Background & Aims:Chronic Hepatitis C (CHC), the leading cause of liver disease, infects more than 185 million people worldwide.The emergence of new molecules that act directly on the virus itself,such as anti-HCV polymerase Sofosbuvir, improved treatment regimens and outcomes. However, in addition to the extremely high cost of this therapy, there is also a risk of selecting viral escape mutant...
BACKGROUND All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3. METHODS In this open-label study, we initially randomly assigned 44 previously untreated pa...
Background and aims. Pegylated interferon (Peg-INF) and ribavirin (RBV) based therapy is suboptimal and poorly tolerated. We evaluated the safety, tolerability and efficacy of a 24-week course of sofosbuvir plus daclatasvir without ribavirin for the treatment of hepatitis C virus (HCV) recurrence after liver transplantation (LT) in both HCV-monoinfected and human immunodeficiency virus (HIV)-H...
OBJECTIVE To determineRapid & End treatment response of patients treated with Sofosbuvir in Chronic Hepatitis C at tertiary care hospital. METHODS It was an observational study conducted at Memon Medical Institute from January 2016 to July 2017. The inclusion criteria for patients was 18 years of age or older, having chronic infection with HCV. Total=201 received sofosbuvir with or without in...
There is currently minimal clinical experience regarding retreatment options for patients failing direct-acting antiviral combination regimens. Here, we report the outcomes of a HCV genotype 1b-infected patient with virologic failure following treatment with daclatasvir and asunaprevir, who was successfully retreated with sofosbuvir plus simeprevir.
Objective: To ascertain the efficacy of sofosbuvir combined with daclatasvir against hepatitis C genotype 3 infection.
 Study Design: Prospective longitudinal study.
 Place and Duration Study: Ayub Teaching Hospital, Abbottabad, Pakistan, from Nov 2018 to Jan 2020.
 Methodology: About 262 patients were treated during study. Patients symptoms associated liver failure, including as...
Development of pangenotypic drugs with high clinical efficacy for the treatment hepatitis C virus (HCV) has changed disease’ management. This encouraged governments to make centralized purchases these drugs. The impact is not known, and our aim evaluate economic outcomes purchase sofosbuvir/velpatastir Colombian health system. Direct medical costs adjusted disease states, complications, adverse...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید